LPV / r 400/100mg/5ml, oral sol., 60ml, bot.
NST
DORALPVR2S-
Valid Article
Account code:
60000
Last Updated on:
24/08/2022, 15:54:42
Former
Code(s):
DORALPRF8S2 DORAMISC552 DORAZFR0552
6.4.2.3 - Protease inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
LOPINAVIR (LPV) / RITONAVIR (r)
Reference List
Therapeutic Action
Fixed-dose combination (FDC) of two antiretrovirals, protease inhibitors (PI)
Indications
HIV infection, in combination with other antiretroviral drugs
- See: Essential drugs, MSF, 2021
- See: Update of recommendations on first- and second-line antiretroviral regimens, WHO, 2019
- See: Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV, WHO, 2018
- See: Medical protocol for Sexual Violence Care, MSF, 2020
Instructions for use
Granules in sachet are intended for paediatric use.
Pellets-in-a-capsule and oral solutions presentations became non-standard according to the WHO 2021 Optimal formulary and Limited-use list for antiretroviral drugs for children:
- oral granules can be used from two weeks (instead of three months) and are easier to administer compared to oral pellets
- with increasing use of integrase inhibitor–based regimens and a preference for granules, oral solution should no longer be required
Storage
Below 25ºC - Protect from sunlight - Protect from humidity